The common need across all our clients is the same: independent, expert assessment of whether the biological rationale and translational assumptions underlying a program are likely to hold — before the cost of finding out otherwise becomes unavoidable.

We work with venture capital and growth equity firms, healthcare-focused investment funds, strategic acquirers, and family offices making direct investments in neural interface technologies and neurotherapeutics.

What these clients share is a need for independent teams cannot maintain in-house — rigorous enough to distinguish durable platforms from compelling but fragile science, and timely enough to inform decisions before capital is committed at the wrong stage.

We work with investors and companies for whom scientific miscalculation in neural interface technologies and neurotherapeutics carries real consequences.

Investment Partners

We work with neurotech, pharma, and biopharma companies developing or advancing neural interface platforms and neurotherapeutic programs.

What these clients share is a need for rigorous, independent review of their own work — to stress-test biological assumptions, identify translational vulnerabilities, and strengthen scientific positioning before regulatory, investor, or partnering scrutiny arrives.

Development Partners

The warning signs are visible earlier than most investors realize — and long before the losses become unavoidable.